Skip to content

Advertisement

  • Research
  • Open Access

Functional improvements in patients with lymphangioleiomyomatosis after sirolimus: an observational study

Contributed equally
Orphanet Journal of Rare Diseases201813:34

https://doi.org/10.1186/s13023-018-0775-9

  • Received: 7 November 2017
  • Accepted: 12 February 2018
  • Published:

Abstract

Background

Sirolimus has been shown to be effective in patients with lymphangioleiomyomatosis (LAM). We wish to summarize our experience using sirolimus and its effectiveness in LAM patients.

Methods

We analyzed data from 98 patients who were diagnosed with definite or probable sporadic LAM based on the European Respiratory Society diagnosis criteria for LAM in 2010 at Peking Union Medical College Hospital and who had received sirolimus during January 2007 to June 2015. The data before and after the initiation of sirolimus therapy included pulmonary function tests, arterial blood gas analysis, 6-min walking distance (6MWD), size of chylous effusion and renal angiomyolipomas (AML), St. George’s Respiratory Questionnaires (SGRQ) and vascular endothelial growth factor-D (VEGF-D) levels. Serum levels of sirolimus and adverse events were collected.

Results

Median follow-up was 2.5 years. Most patients had forced expiratory volume in 1 s (FEV1) values less than 70% predicted or symptomatic chylothorax. The mean changes before and after the initiation of sirolimus were − 31.12 ± 30.78 mL/month and 16.11 ± 36.00 mL/month (n = 18,p = 0.002) for FEV1 change, and − 0.55 ± 0.60 mmHg/month and 0.30 ± 1.19 mmHg/month (n = 17, p = 0.018) for PaO2 change. 6MWD improved from 358.8 ± 114.4 m to 415.6 ± 118.6 m (n = 46, p = 0.004) and SGRQ total score from 57.2 ± 21.0 to 47.5 ± 22.8 (n = 50, p < 0.001). The median VEGF-D concentration decreased to 1609.4 pg/mL from 3075.6 pg/mL after sirolimus therapy (n = 41, p < 0.001). Patients with sirolimus trough levels of 5–9.9 ng/mL had an increase in FEV1 (p < 0.05). Sixty-five percent of patients (13/20) had almost complete resolution of chylous effusions. The most frequent adverse events were mouth ulcers, menstrual disorder, hyperlipidemia and acneiform rash, all were mild.

Conclusion

Long-term use of sirolimus is safe in patients with LAM. LAM patients with FEV1 less than 70% predicted and symptomatic chylothorax are suitable for receiving sirolimus therapy. The maintaining serum trough levels of sirolimus are recommended between 5 to 9.99 ng/mL.

Keywords

  • Lymphangioleiomyomatosis
  • Sirolimus
  • Pulmonary function
  • Chylothorax
  • Adverse events

Background

Lymphangioleiomyomatosis (LAM) is a rare multisystem neoplastic disorder that mostly afflicts women and primarily affects the lung and kidney [1]. The prevalence of sporadic LAM varies, ranging from 1 to 9 per million women in the general population and 30–40% of women with tuberous sclerosis complex (TSC) [2, 3]. Patients with LAM suffer from worsening dyspnea and an increasing number of cysts by computed tomography (CT) detection. Forced expiratory volume in 1 s (FEV1), one of the most important pulmonary function measurements, declines at a rate of 75 to 134 mL per year [4, 5]. The management of LAM, however, focuses on observation and supportive therapy. Few effective medications have been identified to slow disease progression.

Loss of TSC2 gene expression plays a central role in the pathogenesis of LAM [6]. The TSC1/TSC2 complex persistently activates the mammalian target of rapamycin (mTOR) signaling pathway, which regulates cellular metabolism, growth and survival. Sirolimus (also called rapamycin), an mTOR inhibitor, maintains mTOR downstream signals and multiple cellular functions at appropriate levels [7]. Sirolimus has been shown to be efficacious in sporadic LAM and TSC-associated patients regarding lung function, lymphatic disease and renal angiomyolipomas in previous studies, including the Multicenter International Lymphangioleiomyomatosis Efficacy and Safety of Sirolimus (MILES) trial [5, 814]. These studies have provided evidence for using sirolimus in LAM patients with moderately severe lung disease, chylothorax, chylous ascites or renal angiomyolipomas. In Peking Union Medical College Hospital (PUMCH), sirolimus has been used in LAM patients since 2007, and much data have been accumulated during this period. This study was aimed at summarizing our experience and providing more evidence regarding the safety, indication, timing and dose of sirolimus.

Methods

Study population

We reviewed records from patients at PUMCH between January 2007 and June 2015. The patients were included if they 1) were diagnosed with definite or probable LAM, based on the European Respiratory Society (ERS) guidelines in 2010 [15] and 2) received sirolimus treatment for at least 12 months. Patients with TSC-associated LAM were excluded in this analysis. The study was part of the LAM registry study of PUMCH. The protocol was approved by the Ethical Committee of PUMCH (S-379). All subjects included in this study signed informed consent documents.

Medication use

Most patients included in this study followed common rules to adjust their sirolimus dose. The initial dose was 2 mg per day if the patient weighed ≥50 kg and 1 mg per day if the patient weighed < 50 kg. The patients were advised to perform a concentration test one month after the initiation of sirolimus. A serum level of 5 to 9.9 ng/mL sirolimus was the target range. Patients with a sirolimus concentration ≥ 10 ng/mL were recommended to reduce the dose by half. For patients with serum levels < 5 ng/mL, if the clinical symptoms were improving according to a physician’s evaluation, the initial dose was continued; if not, the dose of sirolimus was adjusted. After adjustment of the sirolimus dose, the concentration test and symptom evaluation were repeated every 1 to 3 months. The dose of sirolimus was also adjusted due to adverse events or cost burden.

Study design

The records of the included patients were carefully reviewed. We collected the following data: pulmonary function tests, arterial blood gas analysis at rest (on room air), six-minute walking distance (6MWD), St. George’s Respiratory Questionnaire (SGRQ), vascular endothelial growth factor-D (VEGF-D), and response rate of the chylothorax and presence of renal angiomyolipomas by radiological evaluation. We defined baseline data as those collected within 30 days of sirolimus initiation, and additional data were collected 6 months (±3 months), 12 months (±3 months) and ≥15 months after sirolimus initiation. The rate of change in each parameter per month was calculated with data from the most remote two points and time duration. The response of the chylothorax was defined as almost no effusion present on any kind of imaging examination, including chest X-ray, CT and ultrasound, after 6 months without any other interventional or surgical procedures. Adverse events were defined as symptoms that appeared after the therapy was initiated and that lasted for at least 2 days or resulted in abnormal laboratory findings.

Pulmonary function tests were performed according to the ATS/ERS Task Force Standardization of Lung Function Testing in 2005 [16]. The six-minute walking tests were evaluated based on ATS Guidelines for the six-minute walk test [17]. The SGRQs were completed by patients according to the provided instructions [18]. The chylothorax was evaluated by chest X-ray or CT. Renal angiomyolipoma size was evaluated by CT (plain or contrast-enhanced). All imaging was done in a radiology department and interpreted by both radiologists and respiratory physicians. Serum VEGF-D levels were tested by enzyme-linked immunosorbent assay (R&D Systems).

Statistical analysis

The normality of the data was analyzed by Kolmogorov-Smirnov test. Data in normal distribution were reported as means±SD and data in non-normal distribution were reported as median (Q1, Q3). Paired and unpaired T tests were used to compare the differences before and after treatment. All reported p values are two-sided. p values of less than 0.05 were considered statistically significant. All analyses were performed using SPSS software, version 20.0 (IBM, USA).

Results

Patient characteristics

From January 2010 to June 2015, 231 patients were diagnosed with definite or probable sporadic LAM in PUMCH. Of these, 98 patients were enrolled into this study according to the inclusion and exclusion criteria. The number of definite LAM patients was 70, and the number of probable LAM patients was 28. The clinical characteristics of these patients are shown in Table 1. The most frequent reasons for starting sirolimus therapy was FEV1 less than 70% predicted. Four patients started sirolimus for early treatment; three of these patients had rapidly declining pulmonary function, which presented as FEV1 decreasing by more than 90 mL per year but still within the normal range. Another patient had normal and stable pulmonary function. Some patients (3.1%) were treated with sirolimus for unknown reasons because of insufficient data. Median follow-up was 2.5 (2.0, 4.0) years.
Table 1

Baseline demographic and clinical characteristics of patients with lymphangioleiomyomatosis

Characteristics

Numbers (%)

Patients numbers

98

Age-year

21–62

Gender

 

 Female

98 (100)

Race

 Asian

98 (100)

Diagnosis

 Definite LAM

78 (79.6)

 Probable LAM

20 (20.4)

Clinical features

 Postmenopause

5 (5.1)

 Previous pregnancy

76 (77.6)

 Former smoker

0 (0)

 Renal angiomyolipomas

19 (19.4)

 Retroperitoneal angiomyolipomas

2 (2.0)

 History of pneumothorax

42 (42.8)

 History of chylothorax

35 (35.7)

Pulmonary-functionsa

 FEV1 (L)

1.51 ± 0.74

 FEV1/pred (%)

49.03 ± 24.64

 FVC (L)

2.55 ± 0.74

 FVC/pred (%)

76.31 ± 22.99

 FEV1/FVC (%)

51.22 ± 16.53

 PaO2 on room air (mmHg)

65.26 ± 11.39

Reasons for sirolimus-No. (%)

 FEV1 less than 70% predicted

65 (66.3)

 Chylothorax or other lymphatic manifestationsb

22 (22.4)

 Renal angiomyolipoma

4 (4.1)

 Early treatmentc

4 (4.1)

 Unknown reasonsd

3 (3.1)

Types of sirolimus usede

 Rapamune

76 (77.6)

 Yixinke

21 (21.4)

 Saimosi

1 (1.0)

Abbreviations: LAM lymphangioleiomyomatosis, FEV 1 forced expiratory volume in 1 s

aSample size for spirometry and blood gas analysis was 71 and 81 respectively

bIncluding measurable lymphangiomyomas, lymphangiectasis and lymphedema

cIncluding 3 patients with FEV1 annual decreases of more than 90 mL and 1 patient with normal and stable FEV1

dReason for sirolimus could not be identified because of insufficient data

eRapamune, Pfizer Pharmaceuticals Ltd.; Yixinke, North China Pharmaceuticals Co., Ltd.; Saimosi, Hangzhou Sino-American Pharmaceuticals Ltd

Sirolimus improves FEV1 of pulmonary function tests

The rates of change in pulmonary function variables before sirolimus could be obtained for 38 patients (− 22.20±26.07 ml/month), and the rates of change after sirolimus could be obtained for 34 patients (12.23±31.54 ml/month). In 18 patients, the change rates both before and after sirolimus treatment were obtained. In paired comparisons, the mean monthly changes of FEV1 were − 31.12 ± 30.78 mL and 16.11 ± 36.00 mL, respectively (p = 0.002) (Table 2, Fig. 1). FEV1% of predicted value, FVC% of predicted value, FEV1/FVC and DLCO% of predicted value were also improved significantly in paired comparisons (Table 2). Unpaired comparisons before sirolimus and after sirolimus showed similar results except insignificant changes of DLCO (data not shown).
Table 2

Effects of sirolimus on rates of change in pulmonary function and arterial blood gas

Variable

Change per month (Paired)

Before sirolimus

After sirolimus

P value

Pulmonary Function

(N = 18)

 

 FEV1 (mL)

−31.12 ± 30.78

16.11 ± 36.00

0.002

 FEV1/pred (%)

−0.95 ± 0.82

0.30 ± 0.89

< 0.001

 FVC/pred (%)

−1.13 ± 0.93

0.71 ± 1.36

0.001

 FEV1/FVC (%)

−0.82 ± 1.36

0.78 ± 2.16

0.019

 RV/pred (%)

2.50 ± 9.01

0.16 ± 8.30

0.497

 TLC/pred (%)

1.02 ± 4.49

1.15 ± 6.20

0.953

 RV/TLC (%)

0.78 ± 2.38

0.41 ± 2.58

0.688

 DLCO/pred (%)

−0.72 ± 1.34

1.10 ± 2.28

0.043

Arterial Blood Gas

(N = 17)

 

 PaO2 (mmHg)

−0.55 ± 0.60

0.30 ± 1.19

0.018

 PaCO2 (mmHg)

0.005 ± 0.327

0.058 ± 0.194

0.170

 P(A-a)O2 (mmHg)

0.31 ± 0.92

−0.75 ± 1.28

0.037

Abbreviations: FEV 1 forced expiratory volume in 1 s, FVC forced vital capacity, RV residual volume, TLC total lung capacity, DL CO diffusing capacity for carbon monoxide, P a O 2 partial pressure of oxygen in arterial blood, P a CO 2 partial pressure of carbon dioxide in arterial blood, P (A-a) O 2 alveolar-arterial oxygen gradient

Data are presented as mean ± SD

Fig. 1
Fig. 1

Change in FEV1 before and after sirolimus in paired groups. Zero on the horizontal axis indicates the day on which sirolimus therapy was initiated; negative and positive numbers indicate years before and after the initiation of sirolimus administration, respectively. Abbreviations: FEV1, forced expiratory volume in 1 s

The FEV1 value, FEV1% of predicted value, FVC% of predicted value for the patients were significantly increased after 6 months and ≥15 months on sirolimus relative to the baseline levels (p < 0.05). These variables also increased after 12 months of sirolimus therapy, but these changes were not statistically significant (Table 3). Some patients had FEV1 values above their baseline values after 6 months (85.7%, 12/14), whereas the remaining patients (14.3%, 2/14) showed slight decreases relative to their baseline FEV1 values. All nine patients had FEV1 values greater than (8/9) or equal to (1/9) baseline levels after more than 15 months on sirolimus.
Table 3

Paired comparisons of functional tests from baseline to various time points after sirolimus

Variable

6 month

12 months

≥15 months

Baseline

After sirolimus

P value

Baseline

After sirolimus

P value

Baseline

After sirolimus

P value

Pulmonary function

(N = 14)

(N = 9)

(N = 9)

 FEV1 (L)

1.00 ± 0.42

1.21 ± 0.47

0.002

1.56 ± 0.85

1.70 ± 0.66

0.272

0.99 ± 0.45

1.20 ± 0.59

0.007

 FEV1/pred (%)

36.7 ± 16.8

44.5 ± 18.1

0.003

53.1 ± 29.0

58.5 ± 22.5

0.237

34.7 ± 14.2

43.3 ± 19.3

0.002

 FVC/pred (%)

68.5 ± 26.0

83.0 ± 25.0

0.001

72.4 ± 20.7

82.6 ± 12.5

0.059

62.8 ± 16.6

84.7 ± 17.3

0.007

Arterial blood gas

(N = 21)

(N = 16)

(N = 14)

 PaO2 (mmHg)

63.8 ± 9.2

70.1 ± 14.0

0.017

65.6 ± 13.0

67.9 ± 15.0

0.595

62.1 ± 8.7

71.4 ± 11.2

0.001

 PaCO2 (mmHg)

34.2 ± 3.1

34.5 ± 3.5

0.980

32.9 ± 3.7

31.6 ± 7.3

0.970

33.3 ± 4.3

34.5 ± 4.3

0.238

 P(A-a)O2 (mmHg)

43.1 ± 10.1

43.1 ± 10.1

0.293

45.1 ± 12.7

39.1 ± 16.6

0.083

48.4 ± 10.5

39.5 ± 15.0

0.011

6-min walk test

(N = 22)

(N = 18)

(N = 13)

 6MWD (m)

352.5 ± 143.5

442.2 ± 103.9

< 0.001

367.3 ± 135.5

448.7 ± 100.9

0.001

320.7 ± 138.0

423.3 ± 127.1

0.016

St. George’s Respiratory Questionnaire

(N = 27)

(N = 20)

(N = 16)

 Symptoms score

52.7 ± 23.7

37.6 ± 25.4

0.001

48.1 ± 24.8

32.0 ± 26.7

< 0.001

51.4 ± 21.1

29.4 ± 17.1

< 0.001

 Activity score

68.1 ± 26.0

56.1 ± 25.4

< 0.001

63.8 ± 25.3

51.6 ± 24.7

0.009

70.9 ± 23.2

53.7 ± 25.0

0.001

 Impacts score

53.1 ± 27.0

37.2 ± 27.0

< 0.001

48.4 ± 25.3

32.5 ± 22.9

0.001

55.8 ± 23.7

33.2 ± 21.7

0.001

 Total score

57.6 ± 24.8

43.0 ± 23.7

< 0.001

53.2 ± 23.9

38.2 ± 23.0

< 0.001

59.8 ± 21.9

38.8 ± 19.6

< 0.001

Abbreviations: FEV 1 forced expiratory volume in 1 s, FVC forced vital capacity, P a O 2 partial pressure of oxygen in arterial blood, P a CO 2 partial pressure of carbon dioxide in arterial blood, P (A-a) O 2 alveolar-arterial oxygen gradient, 6MWD six-minute walking distance

Data are presented as means±SD

Four patients were considered as having received early treatment. One patient was in a normal and stable state of lung function and did not have any other obvious manifestations when she started sirolimus therapy. This was a 56-year-old woman who maintained normal pulmonary function test results three years after initiating sirolimus and seven years after receiving a diagnosis of LAM. An additional three patients also had normal pulmonary function tests but showed trends towards rapidly declining FEV1 (> 90 mL per year). Two of these patients were able to reach stable lung function during sirolimus therapy. The FEV1 of the remaining patient decreased by 130 mL per year before sirolimus and 250 mL per year after sirolimus.

Sirolimus improves the oxygen level

Sirolimus significantly improved the arterial oxygen levels and alveolar arterial oxygen gradient according to the rates of change (Table 2) and absolute values at different time points after the therapy (Table 3). When compared with baseline measurements, 71.4% (15/21), 75% (12/16) and 85.7% (12/14) of the patients had higher PaO2 after 6, 12 and ≥15 months on sirolimus. In total, PaO2 was 5 mmHg higher on average after sirolimus treatment than at baseline.

Sirolimus improves the 6-min walking distance (6MWD)

In a paired group analysis (n = 46), the 6MWD was 358.8 ± 114.4 m before sirolimus and 415.6 ± 118.6 m after sirolimus (p < 0.05). The mean increase was 56.8 m. The 6MWD results after 6 months, 12 months and ≥15 months on sirolimus increased significantly compared with baseline data (p < 0.05).

Sirolimus improves the resolution of chylothorax

Twenty patients started sirolimus therapy because of symptomatic chylothorax, and two of these patients were complicated with chylous ascites. Chylous effusions had been present 1.72 ± 2.17 years before the initiation of sirolimus therapy. Before sirolimus therapy, all patients had undergone thoracentesis, and 6 patients had required chest tube drainage. Surgical intervention had been performed in 7 of the 20 patients, including pleurodesis in 3 patients, lymphatic venous anastomosis in 3 patients, ligation of the thoracic duct in 1 patient and lysis of thoracic duct adhesions in 1 patient. One of these patients had undergone both pleurodesis and lymphatic venous anastomosis. These interventions, however, did not prevent the recurrence of pleural effusions in any patient. During sirolimus therapy, 13 patients had almost complete resolution of their pleural effusions, and the response rate reached 65%. Two patients still experienced chylous effusions during sirolimus therapy and required thoracentesis. The results of another 5 patients could not be found in our database.

Two patients started sirolimus therapy for severe lymphatic manifestations and experienced relief during the therapy. One patient was a 34-year-old woman who had her retroperitoneal lymphangiomyoma resected in 2006 and found it recurrent and progressing in size (the maximum diameter was 2.9 cm) in 2012. During sirolimus therapy (2012 to present), the mass decreased and disappeared on abdominal CT in 2016. The other patient, a 44-year-old woman, had multiple retroperitoneal lymphangiomyomas and lymphangiectasis and severe lymphedema in her left lower extremity without chylous effusions or ascites in 2012 and initiated sirolimus at that time. She also experienced relief from the lymphatic manifestations during follow-up.

Effects of sirolimus on angiomyolipomas

Of the 19 patients with renal angiomyolipomas, 11 had angiomyolipomas diameter more than 1 cm. We had follow-up data to 2015 in 6 patients and 5 of them had a decrease in tumor diameter after sirolimus therapy. Another one had her mass resected before initiating sirolimus and did not got any recurrence during sirolimus therapy, for 14 months in data. 2 patients had retroperitoneal angiomyolipomas in their history. One of them had it resected before sirolimus therapy and did not have any recurrence during sirolimus therapy, for 18 months in data. Another one did not undergo follow-up abdominal CT.

Sirolimus improves the quality of life (SGRQ score)

In paired groups (n = 50), symptom scores, activity scores, impact scores and total scores of SGRQ after sirolimus therapy all exhibited significant decrease from the baseline value of 51.2±21.8, 67.1±21.0, 52.7±23.4 and 57.2±21.0 to the after treatment value of 41.0±25.1, 59.9±23.5, 42.3±25.0, and 47.5±22.8 respectively (p < 0.05). The mean decrease in SGRQ total scores was 9.7. SGRQ scores at 6 months, 12 months and 15 months after initiation of sirolimus therapy all declined significantly compared with baseline data (p < 0.05) (Table 3).

Effects of sirolimus on serum VEGF-D concentrations

The median serum VEGF-D concentration was 3075.6 pg/mL (2406.5 pg/mL, 4359.6 pg/mL) before sirolimus and 1609.4 pg/mL (1162.1 pg/mL, 2457.1 pg/mL) after sirolimus (n = 41, p < 0.05). Baseline VEGF-D levels may predict treatment response of oxygen levels. When patients were divided to two groups based on PaO2 changes after treatment (< 0.3 mmHg/month, n = 20 and ≥ 0.3 mmHg/month, n = 20), significant difference of baseline VEGF-D levels, 2665.7 (1723.4, 3144.9) pg/ml and 4589.5 (2140.0, 3475.5) pg/ml respectively, was found (p < 0.05). There was no difference of baseline VEGF-D levels in two groups based on FEV1 changes after treatment (< 4 ml/month, n = 14 and ≥ 4 ml/months, n = 16).

Serum levels of sirolimus

The serum levels of sirolimus were tested at PUMCH in 59 patients. Most patients (72.9%) maintained sirolimus levels between 5 to 9.9 ng/mL. Some patients (20.3%) had sirolimus levels under 5 ng/mL but all above 3 ng/mL. Patients with sirolimus trough levels 5–9.9 ng/mL had significant increases in FEV1 (p < 0.05). Patients with low-dose sirolimus (trough levels 3–4.9 ng/mL) and relatively high-dose (trough levels 10–14.9 ng/mL) showed only a tendency to an increase in FEV1, but the increase was not statistically significant (p > 0.05).

Adverse events potentially related to sirolimus

The most common adverse events were mouth ulcers, menstrual disorder, hyperlipidemia and acneiform rash (Table 4). Almost all adverse events were mild. Only three patients discontinued sirolimus due to severe adverse events, which included elevated liver enzymes, lung infection and fever. All three patients initiated the therapy again after 2 to 6 months and were free of severe adverse events.
Table 4

Adverse events in patients with sirolimusa

Adverse events

Number of patients

Percentage (%)

Mouth ulcers

43

43.9

Menstrual abnormality

26

26.5

Hyperlipidemia

15

15.3

Acneiform rash

15

15.3

Diarrhea

2

2.0

Fever

2

2.0

Peripheral edema

2

2.0

Gingival hyperplasia

2

2.0

Infections

1

1.0

Hypertension

1

1.0

Non-productive cough

1

1.0

Nasal allergy

1

1.0

Low back pain

1

1.0

Chest pain

1

1.0

Alopecia

1

1.0

Toothache

1

1.0

Arthralgia (finger)

1

1.0

Dizziness

1

1.0

Palpitation

1

1.0

Elevated alanine aminotransferase

1

1.0

aThree patients stopped sirolimus because of severe adverse effects, which were elevated liver alanine aminotransferase, lung infection and fever. All of them initiated the therapy again after 2 to 6 months and were free of severe adverse events

Discussion

In the present study, LAM patients, most of whom had damaged pulmonary function and lymphatic manifestations, benefited from sirolimus therapy without severe adverse events. Sirolimus stabilized pulmonary function and arterial partial oxygen pressure, improved quality of life and exercise tolerance, and induced remission of lymphatic manifestations, especially chylothorax. Sirolimus also reduced serum levels of the disease severity associated biomarker VEGF-D.

For functional evaluation, pulmonary function variables are the most direct way to determine the efficacy of sirolimus. Before sirolimus therapy, the patients were experiencing losses in FEV1 of 266.40 mL per year, which was 8.8 times that of the annual loss in healthy people [19]. After sirolimus treatment, FEV1 was remarkably improved to adding 146.76 ml per year that was higher than previous reports [5, 8, 10].

In addition to the patients with severely impaired lung function, we also looked on those patients who had relatively normal lung function. An annual loss of 90 mL or more in the FEV1 value was considered rapidly declining as this is three-fold greater than the normal rate of annual loss in healthy people [19, 20]. Two patients out of three eliminated the FEV1 rapid loss during sirolimus therapy, which reminded us to pay more attention to the declining rate rather than the absolute value of lung function. Another patient who started sirolimus with normal and stable lung function and had persistently stable FEV1 during sirolimus provided physicians with a choice of initiating sirolimus at the time of diagnosis so that the patient’s lung function could be stabilized as early as possible.

Patients evaluated after 15 months of sirolimus therapy still showed stabilization of lung function, which indicated that sirolimus had a sustained effect on the LAM patients. The importance of the observed changes in lung function was further supported by arterial blood gas analysis, 6MWD and SGRQ scores. These results were consistent with those from two long-term observational studies [8, 11]. PaO2 is a comprehensive manifestation of ventilation and gas exchange function, both of which are damaged in LAM patients. Actually, the positive change in PaO2 was in accordance with other variables associated with lung function, indicating that it was also an effective evaluation measurement. The 6MWD was stabilized but not improved after sirolimus in the MILES trial [5]. In another observation of only 5 patients, 6MWD significantly improved after sirolimus [21]. The patients in our study showed a significant increase of 57 m, which demonstrated the sirolimus-related effects on exercise tolerance. SGRQ was used in our study to evaluate the quality of life, representing overall status of health of patients. Our results suggested SGRQ was sensitive showing treatment response after sirolimus. In our previous study, we found SGRQ is correlated with Borg scale of breathlessness, 6MWD, oxygen and pulmonary functions in LAM patients [22]. Quality of life improvement after sirolimus was also reported in MILES study evaluated with EuroQoL visual-analogue scale and Functional Performance Inventory [5]. MILES study also confirmed the correlations of SGRQ and FEV1, DLCO, and 6MWD [23]. Exercise capacity and health-related quality of life are important outcomes in LAM patients.

At least 65% of the patients (13/20) who had symptomatic chylothorax had favorable responses to sirolimus in our study. Taveira-DaSilva reported that all 12 patients with chylous effusions experienced resolution of this condition, and 9 of these patients had complete resolution [10]. Another study showed that chylothorax resolved completely within 1 to 5 months of sirolimus therapy in 6 of 7 cases. Several case reports have also supported the effectiveness of sirolimus in the remission of chylous effusions [2428].

With respect to dosing, the sirolimus dose was generally adjusted to maintain a serum trough level between 5 and 15 ng/mL [5, 10, 11, 29]. A Japanese and a recent United Kingdom study suggested that low-dose sirolimus, which resulted in serum trough levels lower than 5 ng/mL, was also effective in stabilizing lung function and resolving chylothorax [9, 30]. In our study, however, patients with low-dose sirolimus (trough levels 3–4.9 ng/mL) showed increases in FEV1, but this change was not statistically significant (p > 0.05). We should pay attention to the fact that the number of patients was small (n = 5). Interestingly, adjusting sirolimus dose to serum trough levels being 5–9.9 ng/mL, but not 5–15 ng/mL, was effective enough to improve lung function in LAM patients.

This study described our experience of using sirolimus in a real practice with LAM patients. There are several limitations. The follow-up evaluations were not comprehensive due to irregular follow-up, unwillingness to be evaluated, or inability to be evaluated due to health status or medical costs. Second, the sample sizes in some subgroup analyses were small. We are now performing an updated version of a registry study of LAM using a nation-wide sample from China (LAM-China, ClinicalTrials.gov# 03193892). Patients in the LAM-China study will be evaluated annually.

Conclusion

Sirolimus is effective in stabilizing or improving pulmonary function, blood oxygen levels, exercise capacity, and quality of life in patients with LAM. Sirolimus is effective in the treatment of LAM-related chylothorax. Sirolimus also decreases the VEGF-D levels, a biomarker of LAM disease severity. Sirolimus is safe in long-term use with a median follow-up of 2.5 years. A dose of sirolimus between 5 and 9.9 ng/mL is appropriate.

Abbreviations

6MWD: 

6-min walking distance

AML: 

Angiomyolipomas

DLCO

Diffusing capacity for carbon monoxide

ERS: 

European Respiratory Society

FEV1

Forced expiratory volume in 1 s

FVC: 

Forced vital capacity

LAM: 

Lymphangioleiomyomatosis

MILES: 

Multicenter International Lymphangioleiomyomatosis Efficacy and Safety of Sirolimus

mTOR: 

Mammalian target of rapamycin

P(A-a)O2

Alveolar-arterial oxygen gradient

PaCO2

Partial pressure of carbon dioxide in arterial blood

PaO2

Partial pressure of oxygen in arterial blood

PUMCH: 

Peking Union Medical College Hospital

RV: 

Residual volume

SGRQ: 

St. George’s Respiratory Questionnaires

TLC: 

Total lung capacity

TSC: 

Tuberous sclerosis complex

VEGF-D: 

Vascular endothelial growth factor-D

Declarations

Acknowledgements

The authors are grateful to the patients for their contribution.

Funding

This work was supported by the National Key Research and Development Program of China (2016YFC0901502), Beijing Municipal Science and Technology Project (Z151100003915126), and the National Natural Science Foundation of China (81570061).

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author.

Authors’ contributions

YZ and LS were involved in the study design, data analysis and manuscript drafting. WX, XW, JW, XL participated in clinical evaluation of the patients. WZ participated in radiology evaluation of the patients. XT and YY participated in clinical evaluation and manuscript drafting. KFX were involved in the study design, performed clinical evaluation of the patients and critical evaluation of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study was part of the LAM registry study of PUMCH. The protocol was approved by the Ethical Committee of Peking Union Medical College Hospital (S-379). All subjects included in this study signed informed consent documents.

Consent for publication

Consent for publication was obtained from all participants.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Respiratory Medicine, Peking Union Medical College Hospital, Beijing, China
(2)
Department of Radiology, Peking Union Medical College Hospital, Beijing, China

References

  1. Thway K, Fisher C. PEComa: morphology and genetics of a complex tumor family. Ann Diagn Pathol. 2015;19:359–68.View ArticlePubMedGoogle Scholar
  2. Kristof AS, Li PZ, Major P, Landry JS. Lymphangioleiomyomatosis and tuberous sclerosis complex in Quebec: prevalence and health-care utilization. Chest. 2015;148:444–9.View ArticlePubMedGoogle Scholar
  3. Harknett EC, Chang WYC, Byrnes S, Johnson J, Lazor R, Cohen MM, et al. Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis. QJM. 2011;104:971–9.View ArticlePubMedGoogle Scholar
  4. Taveira-DaSilva AM, Stylianou MP, Hedin CJ, Hathaway O, Moss J. Decline in lung function in patients with Lymphangioleiomyomatosis treated with or without progesterone. Chest. 2004;126:1867–74.View ArticlePubMedGoogle Scholar
  5. McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364:1595–606.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Glasgow CG, Steagall WK, Taveira-Dasilva A, Pacheco-Rodriguez G, Cai X, El-Chemaly S, et al. Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies. Respir Med. 2010;104:S45–58.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168:960–76.View ArticlePubMedGoogle Scholar
  8. Yao J, Taveira-DaSilva AM, Jones AM, Julien-Williams P, Stylianou M, Moss J. Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis. Am J Respir Crit Care Med American Thoracic Society. 2014;190:1273–82.View ArticleGoogle Scholar
  9. Ando K, Kurihara M, Kataoka H, Ueyama M, Togo S, Sato T, et al. Efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis. Respir Investig. 2013;51:175–83.View ArticlePubMedGoogle Scholar
  10. Taveira-DaSilva AM, Hathaway O, Stylianou M, Moss J. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann Intern Med. 2011;154:797–805.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Taveira-DaSilva AM, Jones AM, Julien-Williams P, Stylianou M, Moss J. Long-term effect of sirolimus on serum VEGF-D levels in patients with lymphangioleiomyomatosis. Chest. 2018;153(1):124–32.View ArticlePubMedGoogle Scholar
  12. Hecimovic A, Jakopovic M, Pavlisa G, Jankovic M, Vukic-Dugac A, Redzepi G, et al. Successful treatment of pulmonary and lymphatic manifestations of lymphangioleiomyomatosis with sirolimus. Lymphology. 2015;48:97–102.PubMedGoogle Scholar
  13. Freitas CSG, Baldi BG, Araújo MS, Heiden GI, Kairalla RA, Carvalho CRR. Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations. J Bras Pneumol. 2015;41:275–80.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Davies DM, de Vries PJ, Johnson SR, McCartney DL, Cox JA, Serra AL, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res American Association for Cancer Research. 2011;17:4071–81.View ArticleGoogle Scholar
  15. Johnson SR, Cordier JF, Lazor R, Cottin V, Costabel U, Harari S, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur. Respir. J. European respiratory. Society. 2010;35:14–26.Google Scholar
  16. Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, et al. Standardisation of the measurement of lung volumes. Eur. Respir. J. European respiratory Society. 2005;26:511–22.View ArticleGoogle Scholar
  17. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am. J. Respir. Crit. Care Med. American Thoracic Society. 2002;166:111–7.View ArticleGoogle Scholar
  18. Jones PW, Quirk FH, Baveystock CM. The St George's respiratory questionnaire. Respir Med. 1991;85:25–31.View ArticlePubMedGoogle Scholar
  19. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365:1184–92.View ArticlePubMedGoogle Scholar
  20. McCormack FX, Gupta N, Finlay GR, Young LR, AM T-DS, Glasgow CG, et al. Official American Thoracic Society/Japanese respiratory society clinical practice guidelines: Lymphangioleiomyomatosis diagnosis and management. Am J Respir Crit Care Med. 2016;194:748–61.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Neurohr C, Hoffmann AL, Huppmann P, Herrera VA, Ihle F, Leuschner S, et al. Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis? Respir Res BioMed Central. 2011;12:66.Google Scholar
  22. Xu K-F, Wang L, Tian X-L, Gui Y-S, Peng M, Cai B-Q, et al. The St. George's respiratory questionnaire in Lymphangioleiomyomatosis. Chin Med Sci J. 2010;25:140–5.View ArticlePubMedGoogle Scholar
  23. Swigris JJ, Lee H-S, Cohen M, Inoue Y, Moss J, Singer LG, et al. St. George's respiratory questionnaire has longitudinal construct validity in Lymphangioleiomyomatosis. Chest. 2013;143(6):1671–8.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Barrera P, Simons SO, Luijk B, Wessels MJC, Heijdra YF. Efficacy of sirolimus therapy for chylous effusions in lymphangioleiomyomatosis. Ann Am Thorac Soc. American Thoracic Society. 2013;10:408–9.View ArticleGoogle Scholar
  25. Chachaj A, Drozdz K, Chabowski M, Dziegiel P, Grzegorek I, Wojnar A, et al. Chyloperitoneum, chylothorax and lower extremity lymphedema in woman with sporadic lymphangioleiomyomatosis successfully treated with sirolimus: a case report. Lymphology. 2012;45:53–7.PubMedGoogle Scholar
  26. Ellender CM, Williams TJ, Gooi J, Snell GI, Whitford HM. Management of refractory chylothorax in pulmonary lymphangioleiomyomatosis. Respirol Case Rep. 2015;3:72–4.PubMedPubMed CentralGoogle Scholar
  27. Ohara T, Oto T, Miyoshi K, Tao H, Yamane M, Toyooka S, et al. Sirolimus ameliorated post lung transplant chylothorax in lymphangioleiomyomatosis. Ann Thorac Surg. 2008;86:e7–8.View ArticlePubMedGoogle Scholar
  28. Rozenberg D, Thenganatt J. Dramatic response to sirolimus in lymphangioleiomyomatosis. Can Respir J Hindawi Publishing Corporation. 2013;20:413–4.View ArticleGoogle Scholar
  29. Takada T, Mikami A, Kitamura N, Seyama K, Inoue Y, Nagai K, et al. Efficacy and safety of long-term Sirolimus therapy for Asian patients with Lymphangioleiomyomatosis. Ann Am Thorac Soc American Thoracic Society. 2016;13:1912–22.View ArticleGoogle Scholar
  30. Bee J, Fuller S, Miller S, Johnson SR. Lung function response and side effects to rapamycin for lymphangioleiomyomatosis: a prospective national cohort study. Thorax. 2017;0:1–7.Google Scholar

Copyright

Advertisement